Efficacy of indirect dopamine agonists for psychostimulant dependence: A systematic review and meta-analysis of randomized controlled trials

Journal of Substance Abuse Treatment

Volumn 40, Issue 2, 2011, Pages 109-122

  Pérez Mañá, Clara ^a,b   Castells, Xavier ^b,c,d   Vidal, Xavier ^b,d   Casas, Miguel ^c,d   Capellà, Dolors ^b,c  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF GIRONA   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Amphetamine dependence; Cocaine dependence; Indirect dopamine agonists; Meta analysis; Meta regression

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; DEXAMPHETAMINE; DISULFIRAM; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MAZINDOL; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; PSYCHOSTIMULANT AGENT; SELEGILINE;

ARTICLE; CLINICAL ASSESSMENT; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RETENTION; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; URINALYSIS;

EID: 78951469965     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2010.08.012     Document Type: Article

References (98)

1. Alvarez Y., Farré M., Fonseca F., Torrens M. Anticonvulsant drugs in cocaine dependence: A systematic review and meta-analysis. Journal of Substance Abuse Treatment 2010, 38:66-73.
2. Amato L., Minozzi S., Pani P.P., Davoli M. Antipsychotic medications for cocaine dependence. Cochrane Database of Systematic Reviews 2007, 3:CD006306. 10.1002/14651858.CD006306.pub2.
3. Anderson A.L., Reid M.S., Li S.H., Holmes T., Shemanski L., Slee A., et al. Modafinil for the treatment of cocaine dependence. Drug and Alcohol Dependence 2009, 104:133-139.
4. Camp D.M., Browman K.E., Robinson T.E. The effects of methamphetamine and cocaine on motor behavior and extracellular dopamine in the ventral striatum of Lewis versus Fischer 344 rats. Brain Research 1994, 668:180-193.
5. Carroll K.M., Fenton L.R., Ball S.A., Nich C., Frankforter T.L., Shi J., et al. Efficacy of disulfiram and cognitive behaviour therapy in cocaine-dependent outpatients. A randomized placebo controlled trial. Archives of General Psychiatry 2004, 61:264-272.
6. Cartier J., Farabee D., Prendergast M.L. Methamphetamine use, self-reported violent crime, and recidivism among offenders in California who abuse substances. Journal of Interpersonal Violence 2006, 21:435-445.
7. Castells X., Casas M., Pérez-Mañá C., Roncero C., Vidal X., Capellà D. Efficacy of psychostimulant drugs for cocaine dependence. Cochrane Database of Systematic Reviews 2010, 2:CD007380. 10.1002/14651858.CD007380.pub3.
8. Castells X., Casas M., Vidal X., Bosch R., Roncero C., Ramos-Quiroga J.A., et al. Efficacy of central nervous system stimulant treatment for cocaine dependence: A systematic review and meta-analysis of randomised controlled clinical trials. Addiction 2007, 102:1871-1887.
9. Chang L., Alicata D., Ernst T., Volkow N. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction 2007, 102:16-32.
10. Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. Statistics in Medicine 2000, 19:3127-3131.
11. Dackis C.A., Kampman K.M., Lynch K.G., Pettinati H., O'Brien C.P. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005, 30:205-211.
12. Dackis C.A., Lynch K.G., Yu E., Samaha F.F., Kampman K.M., Cornish J.W., et al. Modafinil and cocaine: A double-blind, placebo-controlled drug interaction study. Drug and Alcohol Dependence 2003, 70:29-37.
13. Darke S., Kaye S., Duflou J. Cocaine-related fatalities in New South Wales, Australia 1993-2002. Drug and Alcohol Dependence 2005, 77:107-114.
14. Dias A.C., Ribeiro M., Dunn J., Sesso R., Laranjeira R. Follow-up study of crack cocaine users: Situation of the patients after 2, 5, and 12 years. Substance Abuse 2008, 29:71-79.
15. Elkashef A., Fudala P.J., Gordon L., Li S.H., Kahn R., Chiang N., et al. Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence. Drug and Alcohol Dependence 2006, 85:191-197.
16. Elkashef A.M., Rawson R.A., Anderson A.L., Li S.H., Holmes T., Smith E.V., et al. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 2008, 33:1162-1170.
17. European Monitoring Centre for Drugs and Drug Addition Annual report: The state of the drugs problem in Europe 2009 2009, Retrieved from:. http://www.emcdda.europa.eu/publications/annual-report/2009.
18. George T.P., Chawarski M.C., Pakes J., Carroll K.M., Kosten T.R., Schottenfeld R.S. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: A preliminary trial. Biological Psychiatry 2000, 47:1080-1086.
19. Glasner-Edwards S., Mooney L.J., Marinelli-Casey P., Hillhouse M., Ang A., Rawson R.A. Methamphetamine Treatment Project Corporate Authors. Psychopathology in methamphetamine-dependent adults 3 years after treatment. Drug and Alcohol Review 2010, 29:12-20.
20. Gøtzsche P.C., Hróbjartsson A., Maric K., Tendal B. Data extraction errors in meta-analyses that use standardized mean differences. The Journal of the American Medical Association 2007, 298:430-437.
21. Grabowski J., Rhoades H., Schmitz J., Stotts A., AnnDaruzska L., Creson D., et al. Dextroamphetamine for cocaine-dependence treatment: A double-blind randomized clinical trial. Journal of Clinical Pharmacology 2001, 21:522-526.
22. Grabowski J., Rhoades H., Scotts A., Cowan K., Kopecky C., Dougherty A., et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: Two double-blind randomized clinical trials. Neuropsychopharmacology 2004, 29:969-981.
23. Grabowski J., Roache J.D., Schmitz J.M., Rhoades H., Creson D., Korszun A. Replacement medication for cocaine dependence: Methylphenidate. Journal of Clinical Pharmacology 1997, 17:485-488.
24. Hameedi F.A., Rosen M.I., McCance-Katz E.F., McMahon T.J., Price L.H., Jatlow P.I., et al. Behavioral, physiological, and pharmacological interaction of cocaine and disulfiram in humans. Biological Psychiatry 1995, 37:560-563.
25. Hart C.L., Haney M., Vosburg S.K., Rubin E., Foltin R.W. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 2008, 33:761-768.
26. Higgins J.P.T., Green S. Cochrane handbook for systematic reviews of interventions. Version 5.0.2. The Cochrane Collaboration 2009, [updated September 2009], Retrieved from:. http://www.cochrane-handbook.org.
27. Howell L.L., Kimmel H.L. Monoamine transporters and psychostimulant addiction. Biochemical Pharmacology 2008, 75:196-217.
28. Jüni P., Altman D.G., Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. British Medical Journal 2001, 323:42-46.
29. Kaye S., Darke S., Duflou J., McKetin R. Methamphetamine-related fatalities in Australia: Demographics, circumstances, toxicology and major organ pathology. Addiction 2008, 103:1353-1360.
30. Klein M. Research issues related to development of medications for treatment of cocaine addiction. Annals of the New York Academy of Sciences 1998, 844:75-91.
31. Koob G.F. The neurobiology of addiction: A neuroadaptational view relevant for diagnosis. Addiction 2006, 101S1:23-30.
32. Kuhar M.J., Ritz M.C., Boja J.W. The dopamine hypothesis of the reinforcing properties of cocaine. Trends in Neurosciences 1991, 14:299-302.
33. Kuhns J.B., Wilson D.B., Maguire E.R., Ainsworth S.A., Clodfelter T.A. A meta-analysis of marijuana, cocaine and opiate toxicology study findings among homicide victims. Addiction 2009, 104:1122-1131.
34. Kvernmo T., Houben J., Sylte I. Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Current Topics in Medicinal Chemistry 2008, 8:1049-1067.
35. Lee B., London E.D., Poldrack R.A., Farahi J., Nacca A., Monterosso J.R., et al. Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. Journal of Neuroscience 2009, 29:14734-14740.
36. Levin F.R., Evans S.M., Brooks D.J., Garawi F. Treatment of cocaine dependent treatment seekers with adult ADHD: Double-blind comparison of methylphenidate and placebo. Drug and Alcohol Dependence 2007, 87:20-29.
37. Lima M.S., Reisser A.A., Soares B.G., Farrell M. Antidepressants for cocaine dependence. Cochrane Database of Systematic Reviews 2003, 2:CD002950. 10.1002/14651858.CD002950.
38. Malcolm R., Swayngim K., Donovan J.L., DeVane C.L., Elkashef A., Chiang N., et al. Modafinil and cocaine interactions. American Journal of Drug and Alcohol Abuse 2006, 32:577-587.
39. Marek G.J., Vosmer G., Seiden L.S. Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine upon dopaminergic neurons. Brain Research 1990, 513:274-279.
40. Margolin A., Avants K., Malison R.T., Kosten T.R. High- and low-dose mazindol for cocaine dependence in methadone-maintained patients: A preliminary evaluation. Substance Abuse 1997, 18:125-131.
41. Margolin A., Avants S.K., Kosten T.R. Mazindol for relapse prevention to cocaine abuse in methadone-maintained patients. American Journal of Drug and Alcohol Abuse 1995, 21:469-481.
42. Margolin A., Kosten T.R., Avants S.K., Wilkins J., Ling W., Beckson M., et al. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug and Alcohol Dependence 1995, 40:125-131.
43. Mattick R.P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews 2009, CD002209. 10.1002/14651858.CD002209.pub2.
44. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2008, CD002207. 10.1002/14651858.CD002207.pub3.
45. McCance-Katz E.F., Kosten T.R., Jatlow P. Disulfiram effects on acute cocaine administration. Drug and Alcohol Dependence 1998, 52:27-39.
46. Minozzi M., Amato L., Pani P.P., Vecchi S., Davoli M. Anticonvulsants for cocaine dependence'. Cochrane Database of Systematic Reviews 2007, 2:CD006754. 10.1002/14651858.CD006754.pub2.
47. Mooney M.E., Herin D.V., Schmitz J.M., Moukaddam N., Green C.E., Grabowski J. Effects of oral methamphetamine on cocaine use: A randomized, double-blind, placebo-controlled trial. Drug and Alcohol Dependence 2009, 101:34-41.
48. Mooney M.E., Schmitz J.M., Moeller F.G., Grabowski J. Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: Two double-blind, randomized clinical trials. Drug and Alcohol Dependence 2007, 88:14-223.
49. Negus S.S., Mello N.K. Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a second-order schedule in rhesus monkeys. Drug and Alcohol Dependence 2003, 70:39-52.
50. Negus S.S., Mello N.K. Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a progressive-ratio schedule in rhesus monkeys. Psychopharmacology 2003, 167:324-332.
51. Negus S.S., Mello N.K., Blough B.E., Baumann M.H., Rothman R.B. Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate "agonist" medications for cocaine dependence: Studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys. The Journal of Pharmacology and Experimental Therapeutics 2007, 320:627-636.
52. Newton T.F., Roache J.D., De la Garza R.I.I., Fong T., Wallace C.L., Li S.H., et al. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 2006, 31:1537-1544.
53. Pavarin R.M. Cocaine consumption and death risk: A follow-up study on 347 cocaine addicts in the metropolitan area of Bologna. Annali Dell'Istituto Superiore Di Sanità 2008, 44:91-98.
54. Pérez-Mañá C., Castells X., Vidal X., Casas M., Capellà D. Safety of indirect dopamine agonists (IDA) for psychostimulant dependence. A systematic review and meta-analysis of randomized controlled trials. 16th World Congress on Basic and Clinical Pharmacology. Copenhagen, Denmark. 17-23 July 2010. Basic & Clinical Pharmacology & Toxicology 2010, 107:146.
55. Perry E.B., Gil R., Miles D., Brenner L., MacDougall L., Johnson R., et al. Mazindol augmentation of antipsychotic treatment for schizophrenic patients with comorbid cocaine abuse or dependence: A preliminary double-blind, randomized, placebo-controlled trial. Journal of Dual Diagnosis 2004, 1:37-47.
56. Petrakis I.L., Carroll K.M., Nich C., Gordon L.T., McCance-Katz E.F., Frankforter T., et al. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 2000, 95:219-228.
57. Pettinati H.M., Kampman K.M., Lynch K.G., Xie H., Dackis C., Rabinowitz A.R. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-ocurring cocaine and alcohol dependence. Addictive Behaviours 2008, 33:651-667.
58. Poling J., Oliveto A., Petry N., Sofuoglu M., Gonsai K., Gonzalez G., et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Archives of General Psychiatry 2006, 63:219-228.
59. Review Manager (RevMan) [computer program]. Version 5.0. 2008, The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen.
60. Robinson J.B. Stereoselectivity and isoenzyme selectivity of monoamine oxidase inhibitors. Enantiomers of amphetamine, N-methylamphetamine and deprenyl. Biochemical Pharmacology 1985, 34:4105-4108.
61. Robinson K.A., Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trails using PubMed. International Journal of Epidemiology 2002, 31:150-153.
62. Rossetti Z.L., Hmaidan Y., Gessa G.L. Marked inhibition of mesolimbic dopamine release: A common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. European Journal of Pharmacology 1992, 221:227-234.
63. Rothman R.B., Glowa J.R. A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909. Molecular Neurobiology 1995, 11:1-19.
64. Rounsaville B.J., Anton S.F., Carroll K., Budde D., Prusoff B.A., Gawin F. Psychiatric diagnoses of treatment-seeking cocaine abusers. Archives of General Psychiatry 1991, 48:43-51.
65. Schmitz J.M., Mooney M.E., Moeller F.G., Stotts A.L., Green C., Grabowski J. Levodopa pharmacotherapy for cocaine dependence: Choosing the optimal behavioral therapy platform. Drug and Alcohol Dependence 2008, 94:142-150.
66. Schubiner H., Saules K.K., Arfken C.L., Johanson C.E., Schuster C.R., Lockhart N., et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology 2002, 10:286-294.
67. Shearer J. Psychosocial approaches to psychostimulant dependence: A systematic review. Journal of Substance Abuse Treatment 2007, 32:41-52.
68. Shearer J. The principles of agonist pharmacotherapy for psychostimulant dependence. Drug and Alcohol Review 2008, 27:301-308.
69. Shearer J., Darke S., Rodgers C., Slade T., van Beek I., Lewis J., et al. A double blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction 2009, 104:224-233.
70. Shearer J., Wodak A., van Beek I., Mattick R.P., Lewis J. Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction 2003, 98:1137-1141.
71. Shoptaw S., Heinzerling K.G., Rotheram-Fuller E., Kao U.H., Wang P.C., Bholat M.A., et al. Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence. Journal of Addictive Diseases 2008, 13-23:27.
72. Shoptaw S., Heinzerling K.G., Rotheram-Fuller E., Steward T., Wang J., Swanson A.N., et al. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug and Alcohol Dependence 2008, 222-232:96.
73. Shoptaw S., Watson D.W., Reiber C., Rawson R.A., Montgomery M.A., Majewska M.D., et al. Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST). Addiction 2005, 1:78-90.
74. Singleton J., Degenhardt L., Hall W., Zabransky T. Mortality among amphetamine users: A systematic review of cohort studies. Drug and Alcohol Dependence 2009, 105:1-8.
75. Soares B.G., Lima M.S., Reisser A.A., Farrell M. Dopamine agonists for cocaine dependence. Cochrane Database of Systematic Reviews 2003, 2:CD003352. 10.1002/14651858.CD003352.
76. STATA [computer program]. Version 10 2007, Stata Corporation, Computing Resource Center, College Station,Texas.
77. Stine S.M., Krystal J.H., Kosten T.R., Charney D.S. Mazindol treatment for cocaine dependence. Drug and Alcohol Dependence 1995, 39:245-252.
78. Stitzer M.L., Walsh S.L. Psychostimulant abuse: The case for combined behavioral and pharmacological treatments. Pharmacology. Biochemistry, and Behavior 1997, 57:457-470.
79. Stretesky P.B. National case-control study of homicide offending and methamphetamine use. Journal of Interpersonal Violence 2009, 24:911-924.
80. Substance Abuse and Mental Health Services Administration Results from the 2008 National Survey on Drug Use and Health: National findings 2009, Office of Applied Studies, Rockville, MD, (NSDUH Series H-36, HHS Publication No. SMA 09-4434).
81. Sulzer D., Sonders M.S., Poulsen N.W., Galli A. Mechanisms of neurotransmitter release by amphetamines: A review. Progress in Neurobiology 2005, 75:406-433.
82. Tendal B., Higgins J.P., Jüni P., Hróbjartsson A., Trelle S., Nüesch E., et al. Disagreements in meta-analyses using outcomes measured on continuous or rating scales: Observer agreement study. British Medical Journal 2009, b3128:339.
83. Thompson P.M., Hayashi K.M., Simon S.L., Geaga J.A., Hong M.S., Sui Y., et al. Structural abnormalities in the brains of human subjects who use methamphetamine. The Journal of Neuroscience 2004, 24:6028-6036.
84. Tiihonen J., Kuoppasalmi K., För J., Tuomola P., Kuikanmäki O., Vorma H., et al. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. The American Journal of Psychiatry 2007, 164:160-162.
85. Torrens M., Fonseca F., Mateu G., Farré M. Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug and Alcohol Dependence 2005, 78:1-22.
86. Vincent N., Schoobridge J., Ask A., Allsop S., Ali R. Physical and mental health problems in amphetamine users from metropolitan Adelaide, Australia. Drug and Alcohol Review 1998, 17:187-195.
87. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Leonido-Yee M., Franceschi D., et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. American Journal of Psychiatry 2001, 158:377-382.
88. Volkow N.D., Fowler J.S., Wang G.J., Hitzermann R., Logan J., Gatley S.J., et al. Decreased dopamine D3 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 1993, 14:169-177.
89. Volkow N.D., Fowler J.S., Wang G.J., Swanson J.M. Dopamine in drug abuse and addiction: Results from imaging studies and treatment implications. Molecular Psychiatry 2004, 9:557-569.
90. Volkow N.D., Fowler J.S., Wolf A.P., Schlyer D., Shiue C.Y., Alpert R., et al. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. American Journal of Psychiatry 1990, 147:719-724.
91. Volkow N.D., Wang G.J., Fischman M.W., Foltin R.W., Fowler J.S., Abumrad N.N., et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 1997, 386:827-830.
92. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Gatley S.J., Hitzemann R., et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 1997, 386:830-833.
93. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Hitzemannn R., Gatley S.J., et al. Cocaine uptake is decreased in the brain of detoxified cocaine abusers. Neuropsychopharmacology 1996, 14:159-168.
94. Wagner G.C., Ricaurte G.A., Seiden L.S., Schuster C.R., Miller R.J., Westley J. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Research 1980, 181:151-160.
95. Wilson J.M., Kalasinsky K.S., Levey A.I., Bergeron C., Reiber G., Anthony R.M., et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nature Medicine 1996, 2:699-703.
96. Wise R.A. Neurobiology of addiction. Current Opinion in Neurobiology 1996, 6:243-251.
97. Zahniser N.R., Sorkin A. Trafficking of dopamine transporters in psychostimulant actions. Seminars in Cell & Developmental Biology 2009, 20:411-417.
98. Zweben J.E., Cohen J.B., Christian D., Galloway G.P., Salinardi M., Parent D., et al. Methamphetamine Treatment Project. Psychiatric symptoms in methamphetamine users. The American Journal on Addictions 2004, 13:181-190.